Six biotech companies went public over the course of three days this week, and three more are expected before the month is out. That puts biotech on a pace not seen since the frothy days of its most recent boom — a boom that was quickly followed by a painful correction that could repeat itself if biotech once more goes over its skis.

The week’s IPOs mark 29 for the year, and if all goes according to plan, biotech will see 31 companies go public before the first half of 2018 wraps up — more than in the entirety of 2012.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy